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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is 
Platelet-Rich Plasma (PRP) a more effective treatment in reducing pain than corticosteroid (CS) 
injections in musculoskeletal injuries?” 
 
STUDY DESIGN: Review of three, double blind, randomized controlled trials (RCTs), 
published between 2013 and 2016, all in the English language were included. The articles 
compared platelet-rich plasma (PRP) and corticosteroid (CS) injections to a visually matched 
placebo of saline in regard to reduction of pain from baseline in varying different 
musculoskeletal injuries. 
 
DATA SOURCES: Three RCTs were found using PubMed and Google Scholar. All articles 
were published in peer reviewed journals and selected based on their correlation to the topic of 
choice, the date of publication, and their ability in evaluating POEMs.  
 
OUTCOMES MEASURED: Patient reported pain level, as measured by visual analog scale 
(VAS) score as well was joint specific scoring, such as the Patient-Rated Tennis Elbow 
Evaluation (PRTEE). 
 
RESULTS: Forogh et al. and Mahindra et al. determined that both PRP and CS injections 
significantly reduced pain in knee osteoarthritis and chronic plantar fasciitis, respectively. 
However, Forogh et al. concluded that PRP had significantly better outcomes at 2 and 6 months 
follow up. Mahindra et al. concluded that CS injections had better outcomes at 3 weeks and 3 
months follow up, whereas, PRP injections showed better outcomes at 3 months follow up. 
Krogh et al. determined that there was no significant difference in pain reduction comparing CS 
and PRP injections to a placebo injection.  
 
CONCLUSION: Based off the data collected from the three RCTs, it is inconclusive whether 
platelet-rich plasma is a more effective treatment that corticosteroid injections in musculoskeletal 
injuries. 
 
KEYWORDS: Platelet-Rich Plasma, Corticosteroids, Musculoskeletal Injuries
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INTRODUCTION 
 
 Musculoskeletal injuries are very prevalent causes of morbidity in the United States 
today. Many of these injuries can be attributed to the elder population and may include 
osteoarthritis and falls.1 The most common cause of injury in the youth population can be 
attributed to trauma such as motor vehicle accidents and sports injuries.1 There are many 
different mechanisms, pharmacological therapies, and procedures that may be used to treat 
varying different musculoskeletal injuries. Treatment may be based on the part of the body 
injured or the structure of the body that has been injured.  
 Musculoskeletal injuries can be defined as any condition or injury that affect the bones, 
joints, or muscles.6 These can be painful, even debilitating, and can affect the everyday quality of 
life, activity, and productivity in these individuals. Over 6.8 million United States residents 
sought out medical care due to musculoskeletal related injuries in 2012.1 Of these reported 
statistics, injuries most commonly occurred in the 18-64-year-old age range with sprains and 
strains accounting for a majority of these injuries.1 Arthritis is the most common cause of 
disability, with approximately half of the United States population over the age of 65 being 
affected by this condition.6 In the year of 2011, the cost burden of these such musculoskeletal 
injuries in the United States costed approximately $213 billion.6 Per person, the total cost for 
medical treatment of a musculoskeletal condition averaged about $47, 800 in 2011.6 
Furthermore, approximately 18% of all healthcare visits were related to musculoskeletal 
conditions in 2010.6  Musculoskeletal injuries are clearly a significant contributor to healthcare 
costs and prevalence today. 
 Due to the commonality of musculoskeletal injuries, there are numerous modalities used 
in the treatment of such conditions. Several studies have been completed in the comparison of 
PRP and CS injections with varying outcomes depending on the injury and length of time of 
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treatment.3,4,5 For example, one study on plantar fasciitis found that PRP was more effective long 
term compared to CS, however, another study found that there was no significant difference in 
the outcomes comparing PRP to CS.7,8,9 Other treatment modalities have also been used 
commonly in the treatment of musculoskeletal injuries. These treatments can include other types 
of injections, including hyaluronic acid, also physical therapy or occupational therapy, 
acupuncture or acupressure, osteopathic manipulation, chiropractic care, and therapeutic 
massage, or a combination of these. The decision regarding the treatment modality may be 
provider preference, age, and involved body part of injury.  
A common treatment for varying musculoskeletal injuries is the use of corticosteroid 
(CS) injections as well as an emerging treatment modality for these injuries is the use of platelet-
rich plasma (PRP) injections. Platelet-rich plasma aids in the healing of injured tissues due to its 
introduction of increased concentrations of growth factors as well as bioactive molecules which, 
therefore, creates an optimized healing environment.2,3 The growth factors included have effects 
on cell proliferation, chemotaxis, cell differentiation, and angiogenesis.4 These injections have 
recently been used to aid in wound and bone healing, alloplastic surgeries, as well as healing 
muscle and tendon damage.4 Intra-articular corticosteroid injections are historically and 
frequently used in the treatment of acute as well as chronic inflammatory conditions.3 
Corticosteroid anti-inflammatory properties are a result of the inhibition of anti-inflammatory 
cytokines that block their pathway that leads to the inflammatory actions.3 The effectiveness of 
both of these treatment modalities have been compared in various studies including plantar 
fasciitis, lateral epicondylitis, and knee osteoarthritis, as well as many other musculoskeletal 
injuries.3,4,5 
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OBJECTIVE 
The objective of this selective EBM review is to determine whether or not, “Is Platelet-Rich 
Plasma (PRP) a more effective treatment in reducing pain than corticosteroid (CS) injections in 
musculoskeletal injuries?” 
METHODS 
 Articles were found using PubMed and Google Scholar. Three randomized controlled 
trials were used in this review. Patients older than 18 years of age with a diagnosed 
musculoskeletal injury based on the specific injuries’ criteria were utilized in this study. The 
experimental intervention was platelet-rich plasma injections and corticosteroid injections. The 
control utilized were injections of normal saline.4,5 The reduction of pain from baseline in 
patients receiving PRP injections compared to CS injections were compared at different intervals 
in time as well as compared to various different musculoskeletal injuries.  The outcome 
evaluated in all three studies was the efficacy in reduction of pain when PRP injections were 
used compared to the reduction of pain with CS injections, as demonstrated by the visual analog 
scale (VAS) score in addition to injury specific pain scores. 
 All randomized controlled trials were published in peer reviewed articles, written in the 
English language, and found on PubMed or Google Scholar databases. The keywords used in the 
searches were “platelet-rich plasma,” “corticosteroid,” and “musculoskeletal injuries.” The 
articles were selected based on relevance and that the outcomes of the studied mattered to the 
patients (POEMs). The inclusion criteria were studies that were RCTs published after the year 
2007. Exclusion criteria included patients under the age of 18 years old, those that did not have a 
diagnosed musculoskeletal injury, patients that did not respond to conservative therapy, and 
patients whom have received previous treatment for these injuries with PRP or CS injections.  
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Table 1: Demographics and Characteristics of Included Studies  
 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Forogh1 RCT 41 61.1± 
7.0 
 
-Pain intensity 
a ≥60 in the 
VAS at the 
time of 
admission 
-Pain >3 mo 
-Undergoing at 
least 2 OA 
treatments 
with no benefit 
 
-History of 
collagen 
vascular, CV 
diseases, DM, 
cancer, 
immunosuppres
sion, Hep B or 
C, knee 
injections, 
infection, 
arthroscopy or 
surgery, active 
lumbosacral 
radiculopathy, 
or drug abuse 
2 -PRP: 20 mL 
whole blood, 
2 mL ACD-
A, 
centrifuged or 
12 mins at 
1600 and 
2000 
-CS: 40 mg 
of 
methylpredni
solone acetate 
Mahindra2 RCT 75 30.7 ± 
7.42 
 
33.9 ± 
8.61 
 
35.4 ± 
9.54 
-Heel pain and 
tenderness of 
calcaneal 
tuberosity  
-No response 
to 3 mo of 
conservative 
therapy 
-Use of NSAID 
within 1 week 
of injection 
0 -CS: 40 mg 
methylpredni
solone 
-PRP: 27 mL 
whole blood 
with 3 mL of 
citrate 
dextrose 
centrifuged 
for 12 mins at 
3200rpm 
-Normal 
saline 
 
Krogh3 Dou
ble 
Blin
d 
RCT 
60 >18  -LE symptoms 
for >3 mo 
-US with signs 
of 
tendinopathy 
of at least 
grade 2 
assessed at 
baseline 
-<18 yo 
-CS injection 
within the past 
3 mo 
-Previous tennis 
elbow surgery, 
inflammatory 
diseases, neck 
pain, shoulder 
pain, and other 
chronic 
widespread 
pain syndromes 
 
0 -CS: 1 mL 
triamcinolone 
40 mg/mL 
-Saline: 3 mL 
saline 0.9% 
-PRP: 27 mL 
of whole 
containing 3 
mL sodium 
citrate, 
centrifuged 
for 15 mins at 
3200rpm 
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OUTCOMES MEASURED 
The primary outcome measured in all three studies was change in pain on visual analog 
scale score or injury specific questionnaire from individual baseline. On this scale, patients are 
able to rate their pain on a scale of 0 (no pain) to 10 (worst pain ever experienced). Forogh et al 
utilized the 20-meter-walk test, active and passive knee range of motion, and flexion contracture 
before the injections and again after injection for knee osteoarthritis.3 Mahindra et al. 
incorporated the American Orthopaedic Foot and Ankle Society (AOFAS) and Hindfoot score to 
evaluate chronic plantar fasciitis.4 Krough et al. utilized the Patient-Rated Tennis Elbow 
Evaluation (PRTEE) questionnaire to allow patients to evaluate their pain.5 
RESULTS 
 Two studies compared the efficacy of PRP injections and CS injections to a placebo.4,5 
One study compared the efficacy of PRP directly to CS injections.3 Each study assessed the pain 
for each specific injury at baseline before treatment was given.3,4,5 Forogh et al. evaluated the 
intervention at 2 months, and 6 months, Krogh et al. evaluated the intervention at  3 months, 6 
months, and 12 months, and Mahindra et al. evaluated the intervention at 3 weeks and again at 3 
months.3,4,5 All three studies were double-blinded studies comparing the effectiveness of PRP 
and CS injections in musculoskeletal injuries.3,4,5 
 The study conducted by Forogh et al. comparing platelet-rich plasma versus 
corticosteroid injections in knee osteoarthritis was conducted in Tehran, Iran at the Physical 
Medicine and Rehabilitation Clinic in Firouzgar Hospital.3 Inclusion and exclusion criteria for 
this study can be found in Table 1.  Forogh et al. evaluated 48 knees in 41 patients with 24 knees 
divided evenly into the PRP injection group and CS injection group evenly.3 Of the initial 41 
patients and 48 knees, 2 patients were lost to follow-up and four patients were excluded due to 
seeking other treatment modalities, leaving a total of 39 knees being included in the statistical 
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analysis.3 The PRP was prepared by drawing 20 mL of autologous blood with the addition of 
anticoagulant citrate dextrose solution, Solution A. This then went through two centrifuge 
procedures at 1600 relative centrifugal force (RCF) for 6 minutes and then 2000 RCF for 6 
minutes, which produced 5 mL of PRP.3 This solution was activated by combining 0.5 mL of 
calcium gluconate.3 One mL of Depo-Medrol containing 40mg of methylprednisolone was 
utilized for the CS group.3 Efficacy was evaluated based on the patient reported VAS-based pain 
intensity, 20-meter-walk test, as well as active and passive range of motion.3 Results were 
calculated based on the change from baseline pain, pain at 2 months, and pain at 6 months 
following the injection.3 This data indicated that platelet-rich plasma treatment significantly 
relieved pain at both 2 months and 6 months follow-up, whereas, the corticosteroid treatment 
was only effective in relieving pain at the 2 month follow-up. Statistical significance was set at 
p<0.05 in this study.3 One patient reported dissatisfaction following the PRP injection due to 
increased knee and lumbar pain.3 No other adverse events were reported by participants in this 
study.3 
Table 2: Efficacy in Pain Reduction Evaluated by Mean Change in VAS in Forogh et al. 
 Baseline 2-month 6-month p-value 
Platelet-Rich 
Plasma (N=23) 
81.3 ±13.4 
 
45.1±23.4 44.6±15.6 <0.05 
Corticosteroid 
(N=16) 
77.8±13.8 65.3±19.3 72.5±16.2 <0.05 
 
 Krogh et al. conducted their study comparing the pain efficacy of PRP and CS injections 
to a placebo in patients with lateral epicondylitis (LE) in Denmark in the Rheumatology Unit at 
the Region Hospital Silkeborg after patients were referred by general practitioners, 
rheumatologists, or orthopaedic specialists.4 Patients included and excluded in this study can be 
found in Table 1. The primary efficacy outcome was changes in intensity of pain 3 months after 
the injection using the Patient-Rated Tennis Elbow Evaluation (PRTEE) questionnaire that 
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evaluates pain as a score ranging from 0 to 50 points.4 Three months was the chosen length of 
time evaluated due to the fact that the study gave patients the option to withdraw from the trial if 
they did not achieve a satisfactory treatment response at 3 months.4 Sixty patients with LE were 
included in the study and randomly divided with 20 patients in each arm of the study.4 Each 
injection was ultrasound guided with the elbow bent at 90 degrees.4 The PRP was prepared using 
27 mL of autologous blood mixed with 3 mL of sodium citrate, then centrifuged at 3,200 RCF 
for 15 minutes.4 The CS group was injected with 1mL containing 40mg of triamcinolone and the 
placebo injection consisted of 3 mL of saline.4  After 3 months Krogh et al. determined there was 
no significant difference in pain reduction between any of the groups.4 However, at the one 
month evaluation, CS showed significant improvement in pain compared to the PRP and saline 
placebo groups.4 Due to the large number of drop out participants at 6 and 12 months, these 
results were not included in the study.4 There were no serious adverse events in any of the groups 
with no reports of infections after any injection therapies received.4 
Table 3: Efficacy in Pain Reduction Evaluated by Mean Change in PRTEE in Krogh et al. 
 Baseline Pain at 1 month Pain at 3 months Confidence 
Interval (CI) 
Platelet-Rich 
Plasma 
27.5 -0.5 -6.0 95% 
Corticosteroid 28.0 -9.8 -7.1 95% 
Saline (placebo) 25.0 -1.7 -3.3 95% 
 
Mahindra et al. conducted their study comparing the efficacy in pain reduction of chronic 
plantar fasciitis using PRP, CS, and a placebo injection in India at the Department of 
Orthopaedics, Dayanand Medical College and Hospital.5  The inclusion and exclusion criteria for 
this study is noted in Table 1. The primary efficacy outcome was reduction in pain from baseline 
at 3 weeks and at 3 months following a PRP, CS, or placebo injection utilizing the VAS and the 
American Orthopaedic Foot and Ankle Society (AOFAS) Ankle and Hindfoot score.5 This study 
included 75 patients with chronic plantar fasciitis and randomly divided these patients into three 
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groups evenly.5  Each injection was given at the patient’s point of maximal tenderness in the 
heel.5 The PRP injection was prepared with 27 mL of autologous blood combined with 3 mL of 
citrate dextrose solution and then centrifuged at 3200 RCF for 12 minutes, creating 2.5 to 3 mL 
of PRP.5 2 mL of 40 mg of methylprednisolone was used for the CS injections and the placebo 
group received normal saline.5 In both the PRP and CS groups, mean VAS score decreased 
significantly from pre-injection baseline scores with no significant difference in pain in the 
placebo group at 3 weeks follow-up and 3 months follow-up.5 However, at 3 weeks follow-up the 
CS group received better outcome scores compared to the PRP group and at 3 months the PRP 
groups received better outcome scores compared to the CS group, but this difference was 
determined to not be significant.5 There were no adverse events reported by patients included in 
this study.5 
Table 4: Efficacy in Pain Reduction Evaluated by Mean Change in VAS in Mahindra et al. 
 Pre-injection 3 weeks 3 months p-value 
Platelet-Rich 
Plasma (PRP) 
7.44±1.04 3.76±1.53 2.52±1.71 <0.05 
Corticosteroid 
(CS) 
7.72±1.17 2.84±1.46 3.64±1.62 <0.05 
Placebo (normal 
saline) 
7.56±1.15 7.12±1.12 7.44±1.04 <0.05 
 
DISCUSSION 
 Musculoskeletal injuries are common conditions in the United States and will continue to 
be in the future. Therefore, it is important to determine the method of treatment that is most 
beneficial to patients in the reduction of their pain due to these injuries. Both CS injections and 
PRP injections are widely used treatment modalities for these such injuries today.  
 Forogh et al. determined that pain relief from PRP injections was significantly greater 
than pain relief in those that were treated with corticosteroids.3 Krogh et al. concluded that there 
was no significant difference in reduction of pain at 3 months follow-up when comparing PRP 
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and CS to placebo.4 However, Krogh et al. was able to determine that CS was associated with 
significant short term relief of pain at one month follow up.4 Mahindra et al. determined that both 
PRP and CS injections were effective in reducing pain at three weeks and three months follow 
up, however, PRP had significant better outcomes at three months follow up compared to CS 
threapy.5 
Whereas CS injections are more likely to be covered by insurance, such as Medicare, 
PRP injections are not due to the lack of evidence of this newer procedure.10,11 Therefore, PRP 
injections can range anywhere from $500 to $2000 without insurance coverage.10 CS injections 
can range from $3 to $200.11 Costs of these injections can vary according to location and the 
practitioner performing the injection.11 
Uses for CS and PRP injections include inflammatory arthridities, tendinopathies, and 
nerve compression syndromes with lack of evidence for various conditions.12 Contraindications 
of both CS and PRP injections include periarticular infections, fractures, instability, septic 
arthritis, certain locations on the body, and juxta articular osteoporosis.12 Complications due to 
these injections are very uncommon and may just be due to administration error.12  CS and PRP 
injections are both approved by the FDA.13,14 However, there use of CS epidural spinal injections 
is not approved as well as several different PRP preparation systems.13,14 
Evaluation of data was limited due to small sample sizes, the allowance of individuals to 
drop out if not satisfied, differing prior treatments to trials, activity level post injections, and 
exact preparations of the PRP injections.3,4,5 It is also essential to take note that these studies took 
place in countries other than the United States. Treatments including other ethnicities would be 
beneficial in determining if PRP is more effective in reducing pain for the general population of 
the United States. All three studies also did not evaluate the reduction of pain greater than one 
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year following the injections, allowing this to be another limitation due to the lack of long-term 
efficacy in pain reduction.3,4,5 
CONCLUSION 
 Based on the results of this review, the data is conflicting in whether or not PRP 
injections reduce pain greater that CS injections in musculoskeletal injuries.3,4,5 While all three 
studies reported pain reduction with both the PRP and CS injections, it is unclear which is more 
effective in general.3,4,5 Evaluation of a longer duration would be beneficial in determining the 
reduction of pain long-term following either PRP or CS injections. Future studies can utilize a 
more specific pain rating scale for an injury to that specific structure that is being evaluated 
rather than a generalized pain scale utilized for all injuries for more accurate results in pain 
reduction. It may also be beneficial to educate patients in the trial that it may take time for the 
injection to become effective to prevent withdrawal due to dissatisfaction. In conclusion, these 
three studies indicated that PRP is an effective treatment for musculoskeletal injuries, however, a 
larger sample size, longer duration, and more specific pain scale is needed to completely 
determine its effectiveness when compared to CS injections.  
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